

## PRODUCT ANNOUNCEMENT

Fully Automated Opal® IHC Multiplexing gives Researchers more Freedom to Discover

November 11, 2016 -- SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) BOOTH #226:

PerkinElmer's Opal® Multicolor Immunohistochemistry (IHC) products will be available in early 2017 for use with Leica Biosystems' fully automated BOND RX research staining platform.

These fully automated multiplex kits can visualize up to six biomarkers and a nuclear counterstain on a single tissue section with next day results.

Combining Leica Biosystem's automated research platform with the high sensitivity and specificity of Opal kits, this new solution will allow researchers more confidence in developing reproducible assays that are easy to standardize across laboratories and will enhance the characterization of immune cells and tumor cells in-situ within tissue, increasing consistency, flexibility and speed and reducing labor."

"Automated staining with Opal Multiplex IHC kits is the next step in advancing our Phenoptics™ quantitative pathology system's workflow," said Terry Lo, General Manager Quantitative Pathology Solutions, PerkinElmer. "This innovation is an important part of providing researchers in immunoncology and other fields the tools they need to help lead to scientific breakthroughs. We are pleased to work with Leica to bring higher throughput and walkaway solutions to our customers."

Colin White, VP of Advanced Staining at Leica Biosystems, added, "Leica Biosystems is excited to announce the availability of PerkinElmer's Opal protocol on the BOND RX. Multiplexing offers many benefits to researchers but has traditionally been complex to operationalize. Our collaboration with PerkinElmer enables multiplexing with high levels of usability and automation."

Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately \$2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE or at [www.perkinelmer.com](http://www.perkinelmer.com).

### Media Contacts:

Leica Biosystems:

Kristin O'Neill

+1 847 821 3537

[LBS-GlobalMarketing@leicabiosystems.com](mailto:LBS-GlobalMarketing@leicabiosystems.com)

PerkinElmer:

Brian Willinsky

+1 781 663 5728

[perkinelmerdas@apcoworldwide.com](mailto:perkinelmerdas@apcoworldwide.com)